| 引用本文： |
-
张淑华,程佳芬,李文君,等.阿伦膦酸钠对绝经后妇女骨折的预防作用[J].同济大学学报（医学版）,2010,31(2):51-54. [点击复制]
- ZHANG Shu-hua,CHENG Jia-fen,LI Wen-jun,et al.Effect of alendronate on prevention of fracture in postmenopausal women with osteoporosis[J].同济大学学报（医学版）,2010,31(2):51-54. [点击复制]
|
|
| 摘要: |
| 目的观察阿伦膦酸钠（福善美）对绝经后妇女骨质疏松症骨折的预防作用。方法绝经后骨质疏松妇女105例，随机分为2组：治疗组53例，对照组52例。2组均应用碳酸钙（钙尔奇D）600mg口服，每晚一次，α-D3骨化醇0．25μg口服，每日2次。治疗组加福善美70mg，每周1次口服。各组用药后每年检测腰椎及髂部骨密度（bonemineraldensity，BMD）、骨钙素（boneglaprotein，BGP）、Ⅰ型胶原氨基末端（cross-linked N-telopeptideoftype collagen，NTx）及随访骨折事件发生率。结果福善美治疗组治疗3年，全身BMD均有不同程度提高。腰椎BMD上升16．7％，股骨颈BMD值上升24．2％，与治疗前相比有统计学意义（P〈0．05）。对照组骨密度稍下降，但无统计学意义（P〉0．05），两组相比有统计学意义（P〈0．01）；治疗组仅发生2例骨折事件，对照组发生7例骨折事件，两组相比有统计学意义（P〈0．01）；两纽治疗均无明显不良反应。结论福善美治疗绝经后妇女骨质疏松症疗效肯定，对骨折有显著预防作用．长期治疗无明显不良反应。 |
| 关键词: 阿伦膦酸钠 骨质疏松 绝经后女性 骨折 |
| DOI：10.3969/j. i s sn1008 - 0392.2010.01 .001 .012 |
| 投稿时间：2009-10-16 |
| 基金项目: |
|
| Effect of alendronate on prevention of fracture in postmenopausal women with osteoporosis |
| ZHANG Shu-hua1,CHENG Jia-fen2,LI Wen-jun2,WANG Ji-ying2,CHENG Xiao-yun2,SHENG Chun-jun2 |
| () |
| Abstract: |
| Objective To determine the efficacy of alendronte sodium（Fosamax） on fracture prevention in postmenopausal women with osteoporosis. Methods One hundred and five cases of postmenopausal women with osteoporosis were randomly divided into 2 groups： treatment group （53 cases） and control group（52 cases）. Calcium carbonate（Caltrate D） 600 mg/d and alfacalcidol 0.25μg twice a day were administrated orally in patients of both groups,meanwhile Fosamax 10 mg were taken once a week in treatment group. Bone mineral density（BMD） of lumbar vertebrae and ilium, bone gla protein （BGP） and cross-linked N-telopeptide of type Ⅰ collagen （NTx） were tested every year and the incidence of fracture were followed-up. Results Compared with the baseline value, BMD was significantly increased in the treatment group at the lumbar spine and femoral neck by 16.7% and 24.2% after 3 years treatment of Fosamax（P〈0.05） while BMD declined in the control group（P〉0.05）. The differences between two groups showed statistical significance （P〈0.01）. Only 2 cases of fracture events occurred in the treatment group,as well as 7 cases in the control group（P〈 0.01）. There were no significant adverse reactions in both groups. Conclusion The beneficial effects of Fosamax in postmenopausal women with osteoporosis were confirmed. Fosamax had a preventive effect on fracture and no significant adverse reactions in long-term treatment. |
| Key words: alendronate osteoporosis postmenopausal women fracture |
